Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026GlobeNewsWire • 10/19/26
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?Zacks Investment Research • 10/12/26
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?Zacks Investment Research • 09/17/26
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/16/26
Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management TranscriptSeeking Alpha • 09/08/26
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight ManagementGlobeNewsWire • 09/08/26
Structure Therapeutics to Participate in Upcoming Healthcare Investor ConferencesGlobeNewsWire • 09/03/26
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?Zacks Investment Research • 08/17/26
Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)Seeking Alpha • 06/11/26
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for ObesityGlobeNewsWire • 06/05/26
Structure Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewsWire • 05/26/26
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?Zacks Investment Research • 05/14/26
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsGlobeNewsWire • 05/07/26
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific SessionsGlobeNewsWire • 04/27/26
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General CounselGlobeNewsWire • 04/14/26
Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety MoatSeeking Alpha • 04/08/26